CA2890108C - Method for treating prostate cancer - Google Patents

Method for treating prostate cancer Download PDF

Info

Publication number
CA2890108C
CA2890108C CA2890108A CA2890108A CA2890108C CA 2890108 C CA2890108 C CA 2890108C CA 2890108 A CA2890108 A CA 2890108A CA 2890108 A CA2890108 A CA 2890108A CA 2890108 C CA2890108 C CA 2890108C
Authority
CA
Canada
Prior art keywords
androgen
prostate cancer
cdk8
cells
senexin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2890108A
Other languages
English (en)
French (fr)
Other versions
CA2890108A1 (en
Inventor
Igor Roninson
Mengqian CHEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Carolina
Original Assignee
University of South Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Carolina filed Critical University of South Carolina
Publication of CA2890108A1 publication Critical patent/CA2890108A1/en
Application granted granted Critical
Publication of CA2890108C publication Critical patent/CA2890108C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2890108A 2012-11-01 2013-11-01 Method for treating prostate cancer Active CA2890108C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261721134P 2012-11-01 2012-11-01
US61/721,134 2012-11-01
PCT/US2013/067990 WO2014071143A1 (en) 2012-11-01 2013-11-01 Method for treating prostate cancer

Publications (2)

Publication Number Publication Date
CA2890108A1 CA2890108A1 (en) 2014-05-08
CA2890108C true CA2890108C (en) 2021-03-02

Family

ID=49641849

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2890108A Active CA2890108C (en) 2012-11-01 2013-11-01 Method for treating prostate cancer

Country Status (6)

Country Link
US (1) US9636342B2 (https=)
EP (1) EP2914266B1 (https=)
JP (1) JP6310470B2 (https=)
KR (1) KR20160014568A (https=)
CA (1) CA2890108C (https=)
WO (1) WO2014071143A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106282378A (zh) * 2016-09-28 2017-01-04 湖北工业大学 一种用于细胞周期依赖性蛋白激酶8基因突变检测的试剂及应用
JP7392954B2 (ja) 2017-09-18 2023-12-06 シーゼット・バイオハブ・エスエフ・リミテッド・ライアビリティ・カンパニー トリプルネガティブ乳癌の治療方法
US12281080B2 (en) 2018-08-21 2025-04-22 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
US11014906B2 (en) 2018-08-21 2021-05-25 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
CA3128377A1 (en) * 2019-02-01 2020-08-06 University Of South Carolina Bicyclic pyridine compositions and methods of using the same for cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235034A1 (en) * 2004-11-01 2006-10-19 Nouri Neamati Novel compounds for treatment of cancer and disorders associated with angiogenesis function
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
BR112012023021A2 (pt) * 2010-03-16 2016-05-31 Dana Farber Cancer Inst Inc compostos de indazol e seus usos
US20140309224A1 (en) 2011-09-13 2014-10-16 Roninson Igor B TREATMENT OF DISEASES OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
UA117342C2 (uk) 2012-02-02 2018-07-25 Сенекс Біотекнолоджи Інк. Селективні інгібітори cdk8/cdk19 та їх застосування як протиметастатичних та хіміопрофілактичних засобів у способах лікування раку

Also Published As

Publication number Publication date
US20150272953A1 (en) 2015-10-01
EP2914266A1 (en) 2015-09-09
JP6310470B2 (ja) 2018-04-11
US9636342B2 (en) 2017-05-02
CA2890108A1 (en) 2014-05-08
EP2914266B1 (en) 2019-06-19
WO2014071143A1 (en) 2014-05-08
KR20160014568A (ko) 2016-02-11
JP2016501845A (ja) 2016-01-21

Similar Documents

Publication Publication Date Title
Tsioumpekou et al. Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression
Zhang et al. PI3K/Akt signaling in osteosarcoma
Burbridge et al. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab
Perea et al. CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation
He et al. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
Han et al. Triptolide inhibits the AR signaling pathway to suppress the proliferation of enzalutamide resistant prostate cancer cells
EP3334725B1 (en) Bromodomain and extra terminal (bet) inhibitor and a protein phosphatase 2a (pp2a) activator for treating bet inhibitor resistant cancer
Chen et al. Targeting USP9x/SOX2 axis contributes to the anti-osteosarcoma effect of neogambogic acid
CA2890108C (en) Method for treating prostate cancer
Liu et al. Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway
Chen et al. Therapeutic targeting RORγ with natural product N-hydroxyapiosporamide for small cell lung cancer by reprogramming neuroendocrine fate
Chen et al. Biological functions and research progress of eIF4E
Linkous et al. Novel therapeutic approaches for targeting tumor angiogenesis
EP2773607B1 (en) Treatment of diseases and disorders related to transducin beta-like protein 1 (tbl 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
Tang et al. Mitochondrial outer membrane protein MTUS1/ATIP1 exerts antitumor effects through ROS-induced mitochondrial pyroptosis in head and neck squamous cell carcinoma
Lee et al. A novel imidazopyridine analogue as a phosphatidylinositol 3-kinase inhibitor against human breast cancer
Zhao et al. P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment
Kim et al. Reciprocal positive regulation between TRPV6 and NUMB in PTEN-deficient prostate cancer cells
WO2016186853A1 (en) Methods of targeting ape1/ref-1 to inhibit hypoxia signaling genes
WO2020214896A1 (en) Small molecule inhibitors of gpcr gpr68 and related receptors
Heidari Horestani et al. The intricate interplay between circadian rhythm, androgen signaling, hormone therapy, and cellular senescence in prostate cancer
US20170258793A1 (en) Method for treating prostate cancer
Ye et al. Loss of PI (4, 5) P2 5-phosphatase A contributes to resistance of human melanoma cells to RAF/MEK inhibitors
KR101207981B1 (ko) 호르몬 불응성 전립선암의 예방 또는 치료용 약제학적 조성물 및 그의 스크리닝 방법
Miao et al. A Small Molecule Selectively Targets N-Myc to Suppress Neuroblastoma Cancer Progression

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181101

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241025

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241025